Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?-Reference-Cited by-同舟云学术

Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

Published:2012-11 Issue:6 Volume:10 Page:441-451
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Puig-Junoy Jaume

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF03261878.pdf

Reference25 articles.

1. Reiffen D, Ward MR. Generic drug industry dynamics. Rev Econ Statistics 2005; 87(1): 37–49

2. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87–123

3. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Referencebased pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics 2002; 20(9): 577–91

4. Vogler S, Habl C, Leopold C, et al. Pharmaceutical pricing and reimbursement information (PPRI) report. Vienna, 2008 [online]. Available from URL: http://ppri.oebig.at/index.aspx?Navigation=r%7C2- [Accessed 2011 Feb 19]

5. Danzon PM, Furukawa MF, Cross national evidence on generic pharmaceuticals: pharmacy vs. physician driven markets. NBER Working Paper 17226, July 2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New pricing models for generic medicines to ensure long-term sustainable competition in Europe;Frontiers in Pharmacology;2023-10-09

2. Review of studies reporting actual prices for medicines;Expert Review of Pharmacoeconomics & Outcomes Research;2018-12-07